See more : Jindal Poly Films Limited (JINDALPOLY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of CTI BioPharma Corp. (CTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CTI BioPharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Investeringsforeningen Bankinvest Globale Aktier Baeredygtig Udvikling Akk.A (BAIGAAUAA.CO) Income Statement Analysis – Financial Results
- Unique Fabricating, Inc. (UFABQ) Income Statement Analysis – Financial Results
- Tohto Suisan Co., Ltd. (8038.T) Income Statement Analysis – Financial Results
- Nichiryoku Co.,Ltd. (7578.T) Income Statement Analysis – Financial Results
- Electriq Power Holdings, Inc. (ELIQ) Income Statement Analysis – Financial Results
CTI BioPharma Corp. (CTIC)
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.95M | 0.00 | 0.00 | 3.35M | 26.29M | 25.15M | 57.41M | 16.12M | 60.08M | 34.68M | 0.00 | 0.00 | 319.00K | 80.00K | 11.43M | 127.00K | 80.00K | 16.09M | 29.59M | 24.77M | 16.90M | 6.24M | 502.04K | 100.00K | 13.20M | 11.80M | 9.10M |
| Cost of Revenue | 3.51M | 161.00K | 4.20M | 0.00 | 879.00K | 364.00K | 1.38M | 1.94M | 895.00K | 137.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.24M | 49.00K | 0.00 | 518.00K | 1.10M | 840.00K | 423.00K | 394.00K | -1.02M | -2.20M | -1.90M | -1.60M | 14.30M |
| Gross Profit | 50.43M | -161.00K | -4.20M | 3.35M | 25.41M | 24.78M | 56.03M | 14.18M | 59.18M | 34.54M | 0.00 | 0.00 | 319.00K | 80.00K | 8.19M | 78.00K | 80.00K | 15.57M | 28.49M | 23.93M | 16.47M | 5.84M | 1.53M | 2.30M | 15.10M | 13.40M | -5.20M |
| Gross Profit Ratio | 93.49% | 0.00% | 0.00% | 100.00% | 96.66% | 98.55% | 97.60% | 87.96% | 98.51% | 99.60% | 0.00% | 0.00% | 100.00% | 100.00% | 71.62% | 61.42% | 100.00% | 96.78% | 96.27% | 96.61% | 97.50% | 93.68% | 304.14% | 2,300.00% | 114.39% | 113.56% | -57.14% |
| Research & Development | 36.90M | 39.14M | 25.94M | 24.11M | 36.47M | 32.87M | 64.96M | 76.63M | 86.46M | 33.62M | 62.31M | 34.90M | 27.03M | 30.18M | 51.61M | 72.02M | 61.99M | 68.77M | 101.13M | 89.53M | 58.76M | 44.67M | 26.57M | 27.70M | 29.20M | 27.30M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 17.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 84.83M | 56.20M | 17.63M | 19.16M | 21.18M | 31.44M | 45.31M | 53.96M | 56.24M | 42.29M | 38.24M | 38.29M | 48.04M | 57.73M | 41.61M | 35.32M | 35.30M | 61.72M | 78.52M | 55.64M | 49.80M | 35.27M | 20.42M | 9.80M | 11.60M | 10.10M | 7.60M |
| Other Expenses | 8.51M | -161.00K | 4.20M | 1.32M | 0.00 | 0.00 | -5.08M | 253.00K | 2.72M | 155.00K | 30.05M | 0.00 | 0.00 | 0.00 | -7.79M | 913.00K | 792.00K | -69.96M | 2.29M | 1.34M | 6.70M | 9.39M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| Operating Expenses | 130.23M | 95.33M | 47.77M | 43.26M | 57.65M | 64.30M | 105.19M | 130.84M | 145.42M | 75.91M | 100.55M | 73.19M | 75.07M | 87.90M | 85.44M | 108.25M | 98.09M | 60.53M | 181.94M | 146.51M | 115.26M | 89.33M | 57.43M | 39.70M | 42.70M | 39.00M | 9.40M |
| Cost & Expenses | 133.75M | 95.33M | 47.77M | 43.26M | 58.53M | 64.67M | 106.57M | 132.78M | 146.31M | 76.05M | 100.55M | 73.19M | 75.07M | 87.90M | 88.68M | 108.30M | 98.09M | 61.05M | 183.05M | 147.35M | 115.68M | 89.72M | 56.40M | 37.50M | 40.80M | 37.40M | 23.70M |
| Interest Income | 1.68M | 38.00K | 204.00K | 1.17M | 1.22M | 0.00 | -2.61M | -2.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.14M | 2.42M | 1.03M | 1.52M | 1.73M | 2.04M | 2.83M | 2.49M | 2.68M | 1.54M | 56.00K | 1.04M | 2.33M | 4.81M | 8.56M | 14.83M | 44.58M | 17.56M | 10.99M | 9.33M | 11.24M | 5.99M | 544.29K | 0.00 | 400.00K | 0.00 | 500.00K |
| Depreciation & Amortization | -56.00K | -161.00K | 204.00K | 3.29M | 593.00K | 717.00K | 831.00K | 990.00K | 1.10M | 1.57M | 2.35M | 2.41M | 1.84M | 1.77M | 5.23M | 4.69M | 6.50M | 10.28M | 11.43M | 8.44M | 14.24M | 12.24M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| EBITDA | -79.85M | -95.33M | -47.77M | -37.43M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -39.63M | -98.97M | -58.91M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -229.88M | -112.27M | -98.79M | -62.05M | -40.95M | -34.10M | -22.70M | -21.40M | -11.60M |
| EBITDA Ratio | -148.02% | 0.00% | 0.00% | -1,118.83% | -102.67% | -150.79% | -84.23% | -719.40% | -149.13% | -114.29% | 0.00% | 0.00% | -24,597.49% | -111,022.50% | -1,454.18% | -93,375.59% | -105,916.25% | -464.01% | -776.77% | -453.32% | -144.55% | -995.00% | -8,156.98% | -34,100.00% | -171.97% | -181.36% | -127.47% |
| Operating Income | -79.80M | -95.33M | -47.77M | -40.71M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -41.53M | -101.50M | -62.19M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -240.83M | -122.59M | -98.79M | -83.49M | -55.90M | -37.40M | -27.60M | -25.60M | -14.60M |
| Operating Income Ratio | -147.91% | 0.00% | 0.00% | -1,217.07% | -125.14% | -157.16% | -85.64% | -723.91% | -143.54% | -119.75% | 0.00% | 0.00% | -23,434.17% | -101,948.75% | -676.02% | -104,713.39% | -123,250.00% | -358.77% | -813.77% | -494.99% | -584.68% | -1,338.76% | -11,134.98% | -37,400.00% | -209.09% | -216.95% | -160.44% |
| Total Other Income/Expenses | -13.20M | -2.58M | -4.68M | 688.00K | 3.55M | -1.31M | -3.79M | -4.10M | -8.00M | -2.02M | -190.00K | -429.00K | -20.64M | -13.84M | -102.75M | -5.12M | -37.22M | -44.77M | -11.47M | -7.45M | 48.88M | 9.20M | 4.52M | 1.70M | 3.00M | 2.90M | 1.20M |
| Income Before Tax | -92.99M | -97.91M | -52.45M | -40.02M | -29.35M | -40.83M | -52.95M | -120.76M | -94.23M | -43.55M | -101.69M | -62.62M | -95.40M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -74.29M | -51.38M | -35.70M | -24.60M | -22.70M | -13.40M |
| Income Before Tax Ratio | -172.37% | 0.00% | 0.00% | -1,196.50% | -111.65% | -162.38% | -92.24% | -749.34% | -156.85% | -125.58% | 0.00% | 0.00% | -29,904.39% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,191.23% | -10,235.12% | -35,700.00% | -186.36% | -192.37% | -147.25% |
| Income Tax Expense | -1.95M | 1.73M | 500.00K | 2.29M | 5.28M | 723.00K | -963.00K | -1.60M | -5.32M | -485.00K | -134.00K | 609.00K | -3.41M | 1.79M | -85.79M | -362.00K | 51.35M | 48.78M | -76.87M | 11.21M | 71.36M | 15.19M | 5.06M | 1.70M | 3.40M | 2.90M | 1.70M |
| Net Income | -91.04M | -99.64M | -52.95M | -42.32M | -29.32M | -40.67M | -52.01M | -119.42M | -93.37M | -42.74M | -101.37M | -62.36M | -82.64M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -80.27M | -51.93M | -36.30M | -25.00M | -23.00M | -13.90M |
| Net Income Ratio | -168.76% | 0.00% | 0.00% | -1,265.08% | -111.53% | -161.74% | -90.60% | -741.02% | -155.41% | -123.26% | 0.00% | 0.00% | -25,906.58% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,287.25% | -10,343.54% | -36,300.00% | -189.39% | -194.92% | -152.75% |
| EPS | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| EPS Diluted | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| Weighted Avg Shares Out | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
| Weighted Avg Shares Out (Dil) | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CTI BioPharma Corp. (NASDAQ: CTIC) to Swedish Orphan Biovitrum AB for $9.10 per share is fair to CTI BioPharma shareholders. Halper Sadeh encourages CTI...
CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CTI BioPharma Corp. (NASDAQ: CTIC) to Swedish Orphan Biovitrum AB for $9.10 per share is fair to CTI BioPharma shareholders. Halper Sadeh encourages CTI...
Why Is CTI BioPharma (CTIC) Stock Up 85% Today?
CTI BioPharma (NASDAQ: CTIC ) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agreeing to acquire CTI BioPharma for $1.7 billion.
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.
CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings
CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion. The offer represents a premium of...
Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion
Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based drugmaker said it will offer $9.10 for each share...
Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE...
Sobi to Acquire CTI BioPharma
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI’s Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ — CTI BioPharma (Nasdaq: CTIC) (“CTI”), a commercial biopharmaceutical company focused on the development and commercialization...
Sobi to Acquire CTI BioPharma
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and...
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE , May 4, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of...
Source: https://incomestatements.info
Category: Stock Reports